Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi is conducting a long-term extension study titled ‘A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.’ The study aims to assess the safety and efficacy of amlitelimab in participants with moderate to severe atopic dermatitis who have previously participated in amlitelimab trials. This research is significant as it could provide insights into the long-term management of atopic dermatitis, a chronic skin condition.
The intervention being tested is amlitelimab, administered as a subcutaneous injection. It is designed to treat moderate to severe atopic dermatitis, potentially offering a new therapeutic option for patients with this condition.
The study follows an interventional design with a single-group model and no masking, focusing primarily on treatment. Participants will receive the intervention and be monitored for safety and efficacy over time, with some undergoing drug withdrawal to assess treatment durability.
The study began on August 5, 2022, and is currently recruiting. The last update was submitted on August 29, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This update could positively impact Sanofi’s stock performance and investor sentiment, especially if amlitelimab proves effective and safe. The atopic dermatitis market is competitive, with several companies seeking effective treatments, making this study’s outcomes potentially significant for Sanofi’s positioning.
The study is ongoing, and further details are available on the ClinicalTrials portal.